Alexander Hoetzel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander Hoetzel has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Simone Faller
Department of Anesthesiology and Critical Care Medicine, University Medical Center Freiburg, Hugstetter Str. 55, D-79106 Freiburg, Germany
5 shared publications Torsten Loop
Uniklin Freiburg, Klin Anasthesiol & Intens Med, Freiburg, Germany
5 shared publicationsRene Schmidt
Department of Anesthesiology and Critical Care Medicine University Medical Center Freiburg Freiburg Germany
4 shared publications- Sashko Spassov
Department of Anesthesiology and Critical Care Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
3 shared publications Stefan W. Ryter
3 shared publicationsHartmut Buerkle
Department of Anesthesiology and Critical Care Medicine University Medical Center Freiburg Freiburg Germany
2 shared publications
Latest Publications
- Open Access
- 19 May 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (5) , 1001
Profiling Distinctive Inflammatory and Redox Responses to Hydrogen Sulfide in Stretched and Stimulated Lung Cells
Hydrogen sulfide (H2S) protects against stretch-induced lung injury. However, the impact of H2S on individual cells or their crosstalk upon stretch remains unclear. Therefore, we addressed this issue in vitro using relevant lung cells. We have explored (i) the anti-inflammatory properties of H2S on epithelial (A549 and BEAS-2B), macrophage (RAW264.7) and endothelial (HUVEC) cells subjected to cycling mechanical stretch; (ii) the intercellular transduction of inflammation by co-culturing epithelial cells and macrophages (A549 and RAW264.7); (iii) the effect of H2S on neutrophils (Hoxb8) in transmigration (co-culture setup with HUVECs) and chemotaxis experiments. In stretched epithelial cells (A549, BEAS-2B), the release of interleukin-8 was not prevented by H2S treatment. However, H2S reduced macrophage inflammatory protein-2 (MIP-2) release from unstretched macrophages (RAW264.7) co-cultured with stretched epithelial cells. In stretched macrophages, H2S prevented MIP-2 release by limiting nicotinamide adenine dinucleotide phosphate oxidase-derived superoxide radicals (ROS). In endothelial cells (HUVEC), H2S inhibited interleukin-8 release and preserved endothelial integrity. In neutrophils (Hoxb8), H2S limited MIP-2-induced transmigration through endothelial monolayers, ROS formation and their chemotactic movement. H2S induces anti-inflammatory effects in a cell-type specific manner. H2S limits stretch- and/or paracrine-induced inflammatory response in endothelial, macrophage, and neutrophil cells by maintaining redox homeostasis as underlying mechanism.
- 19 May 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (5) , 1001
Open AccessProfiling Distinctive Inflammatory and Redox Responses to Hydrogen Sulfide in Stretched and Stimulated Lung Cells
Hydrogen sulfide (H2S) protects against stretch-induced lung injury. However, the impact of H2S on individual cells or their crosstalk upon stretch remains unclear. Therefore, we addressed this issue in vitro using relevant lung cells. We have explored (i) the anti-inflammatory properties of H2S on epithelial (A549 and BEAS-2B), macrophage (RAW264.7) and endothelial (HUVEC) cells subjected to cycling mechanical stretch; (ii) the intercellular transduction of inflammation by co-culturing epithelial cells and macrophages (A549 and RAW264.7); (iii) the effect of H2S on neutrophils (Hoxb8) in transmigration (co-culture setup with HUVECs) and chemotaxis experiments. In stretched epithelial cells (A549, BEAS-2B), the release of interleukin-8 was not prevented by H2S treatment. However, H2S reduced macrophage inflammatory protein-2 (MIP-2) release from unstretched macrophages (RAW264.7) co-cultured with stretched epithelial cells. In stretched macrophages, H2S prevented MIP-2 release by limiting nicotinamide adenine dinucleotide phosphate oxidase-derived superoxide radicals (ROS). In endothelial cells (HUVEC), H2S inhibited interleukin-8 release and preserved endothelial integrity. In neutrophils (Hoxb8), H2S limited MIP-2-induced transmigration through endothelial monolayers, ROS formation and their chemotactic movement. H2S induces anti-inflammatory effects in a cell-type specific manner. H2S limits stretch- and/or paracrine-induced inflammatory response in endothelial, macrophage, and neutrophil cells by maintaining redox homeostasis as underlying mechanism.
- 13 May 2019
- Published by Georg Thieme Verlag KG in AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie
- Vol. 54 (05) , 334-346
Pulmonale Hypertonie: anästhesiologisches Management
Zusammenfassung: Das perioperative Management von Patienten mit pulmonaler Hypertonie erfordert von den behandelnden Anästhesisten fundierte Kenntnisse über die zugrunde liegenden Ursachen, die Pathophysiologie, den Einfluss anästhesiologischer und chirurgischer Maßnahmen wie z. B. die mechanische Beatmung sowie intraoperative Behandlungsoptionen. In der präoperativen Vorbereitung gilt es, alle vorliegenden Befunde zu evaluieren, die Belastbarkeit des Patienten zu erheben und die bestehende Dauermedikation zu kennen. Die Basis für einen sicheren intraoperativen Verlauf stellt die Vermeidung einer pulmonalarteriellen Druckerhöhung und Rechtsherzdysfunktion dar. Hierbei gilt es Hypoxie, Hyperkapnie, Azidose, Hypothermie, Stress und eine koronare Hypoperfusion zu verhindern. Bei einem Anstieg des pulmonalarteriellen Drucks können sowohl inhalative, selektive pulmonale Vasodilatatoren, wie Stickstoffmonoxid oder Prostazykline, als auch intravenös Phosphodiesterase-3-Inhibitoren und Phosphodiesterase-5-Inhibitoren eingesetzt werden. Bei einer rechtsventrikulären Dysfunktion oder Dekompensation sollte mittels inotroper Substanzen und Inodilatoren die Herzfunktion unterstützt werden. Abhängig vom Ausmaß der Operation und dem Schweregrad der pulmonalen Hypertonie erfordert die postoperative Betreuung vor allem Expertise und Strukturen, die ein kontinuierliches Monitoring zulassen.
- 13 May 2019
- Published by Georg Thieme Verlag KG in AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie
- Vol. 54 (05) , 334-346
Pulmonale Hypertonie: anästhesiologisches Management
Zusammenfassung: Das perioperative Management von Patienten mit pulmonaler Hypertonie erfordert von den behandelnden Anästhesisten fundierte Kenntnisse über die zugrunde liegenden Ursachen, die Pathophysiologie, den Einfluss anästhesiologischer und chirurgischer Maßnahmen wie z. B. die mechanische Beatmung sowie intraoperative Behandlungsoptionen. In der präoperativen Vorbereitung gilt es, alle vorliegenden Befunde zu evaluieren, die Belastbarkeit des Patienten zu erheben und die bestehende Dauermedikation zu kennen. Die Basis für einen sicheren intraoperativen Verlauf stellt die Vermeidung einer pulmonalarteriellen Druckerhöhung und Rechtsherzdysfunktion dar. Hierbei gilt es Hypoxie, Hyperkapnie, Azidose, Hypothermie, Stress und eine koronare Hypoperfusion zu verhindern. Bei einem Anstieg des pulmonalarteriellen Drucks können sowohl inhalative, selektive pulmonale Vasodilatatoren, wie Stickstoffmonoxid oder Prostazykline, als auch intravenös Phosphodiesterase-3-Inhibitoren und Phosphodiesterase-5-Inhibitoren eingesetzt werden. Bei einer rechtsventrikulären Dysfunktion oder Dekompensation sollte mittels inotroper Substanzen und Inodilatoren die Herzfunktion unterstützt werden. Abhängig vom Ausmaß der Operation und dem Schweregrad der pulmonalen Hypertonie erfordert die postoperative Betreuung vor allem Expertise und Strukturen, die ein kontinuierliches Monitoring zulassen.
- 1 July 2012
- Published by Elsevier in Laboratory Investigation
- Vol. 92 (7) , 999-1012
Kinetic effects of carbon monoxide inhalation on tissue protection in ventilator-induced lung injury
- 1 July 2012
- Published by Elsevier in Laboratory Investigation
- Vol. 92 (7) , 999-1012
Kinetic effects of carbon monoxide inhalation on tissue protection in ventilator-induced lung injury
- 1 June 2012
- Published by Wolters Kluwer Health in Current Opinion in Anaesthesiology
- Vol. 25 (3) , 340-347
Anesthetic considerations for the patient with liver disease
An increasing number of patients requiring surgery are presenting with chronic or end stage liver disease. The management of these patients demands anesthesiologists with in-depth knowledge of the consequences of hepatic dysfunction, the effects on other organs, the risk of surgery, and the impact of anesthesia. Chronic or end stage liver disease is associated with an increased risk of perioperative morbidity and mortality. It is essential to preoperatively assess possible hepatic encephalopathy, pleural effusions, hepatopulmonary syndrome, hepatopulmonary hypertension, hepatorenal syndrome, cirrhotic cardiomyopathy, and coagulation disorders. The application of two scoring systems, that is, Child-Turcotte-Pugh and model for end stage liver disease, helps to estimate the risk of surgery. The use of propofol is superior to benzodiazepines as intravenous narcotics. Although enflurane and halothane are discouraged for maintenance of anesthesia, all modern volatile anesthetics appear comparable with respect to outcome. Fentanyl, sufentanil, and remifentanil as opioids and cis-atracurium for relaxation may be the best choices in liver insufficency. Regional anesthesia is valuable for postoperative pain management. Current studies have employed different anesthetic approaches in the preoperative and intraoperative management in order to improve outcomes of patients with liver disease.
- 1 June 2012
- Published by Wolters Kluwer Health in Current Opinion in Anaesthesiology
- Vol. 25 (3) , 340-347
Anesthetic considerations for the patient with liver disease
An increasing number of patients requiring surgery are presenting with chronic or end stage liver disease. The management of these patients demands anesthesiologists with in-depth knowledge of the consequences of hepatic dysfunction, the effects on other organs, the risk of surgery, and the impact of anesthesia. Chronic or end stage liver disease is associated with an increased risk of perioperative morbidity and mortality. It is essential to preoperatively assess possible hepatic encephalopathy, pleural effusions, hepatopulmonary syndrome, hepatopulmonary hypertension, hepatorenal syndrome, cirrhotic cardiomyopathy, and coagulation disorders. The application of two scoring systems, that is, Child-Turcotte-Pugh and model for end stage liver disease, helps to estimate the risk of surgery. The use of propofol is superior to benzodiazepines as intravenous narcotics. Although enflurane and halothane are discouraged for maintenance of anesthesia, all modern volatile anesthetics appear comparable with respect to outcome. Fentanyl, sufentanil, and remifentanil as opioids and cis-atracurium for relaxation may be the best choices in liver insufficency. Regional anesthesia is valuable for postoperative pain management. Current studies have employed different anesthetic approaches in the preoperative and intraoperative management in order to improve outcomes of patients with liver disease.
- 1 April 2012
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 114 (4) , 747-756
The Volatile Anesthetic Isoflurane Prevents Ventilator-Induced Lung Injury via Phosphoinositide 3-Kinase/Akt Signaling in Mice
Ity among critically ill patients. Volatile anesthetics have been shown to exert anti-inflammatory and organ-protective effects in vivo. We investigated the effects of the volatile anesthetic isoflurane on lung injury during mechanical ventilation. METHODS: C57BL/6N mice were ventilated with a tidal volume of 12 mL/kg body weight for 6 hours in the absence or presence of isoflurane, and, in a second series, with or without the specific phosphoinositide 3-kinase/Akt inhibitor LY294002. Lung injury was determined by comparative histology, and by the isolation of bronchoalveolar lavage for differential cell counting and analysis of cytokine levels using enzyme-linked immunosorbent assays. Lung homogenates were analyzed for protein expression by Western blotting. RESULTS: Mechanical ventilation caused increases in alveolar wall thickening, cellular infiltration, and an elevated ventilator-induced lung injury score. Neutrophil influx and cytokine (i.e., interleukin-1β, and macrophage inflammatory protein-2) release were enhanced in the bronchoalveolar lavage of ventilated mice. The expression levels of the stress proteins hemeoxygenase-1 and heat shock protein-70 were elevated in lung tissue homogenates. Isoflurane ventilation significantly reduced lung damage, inflammation, and stress protein expression. In contrast, phosphorylation of Akt protein was substantially increased during mechanical ventilation with isoflurane. Inhibition of phosphoinositide 3-kinase/Akt signaling before mechanical ventilation completely reversed the lung-protective effects of isoflurane treatment in vivo. CONCLUSIONS: Inhalation of isoflurane during mechanical ventilation protects against lung injury by preventing proinflammatory responses. This protection is mediated via phosphoinositide 3-kinase/Akt signaling....
- 1 April 2012
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 114 (4) , 747-756
The Volatile Anesthetic Isoflurane Prevents Ventilator-Induced Lung Injury via Phosphoinositide 3-Kinase/Akt Signaling in Mice
Ity among critically ill patients. Volatile anesthetics have been shown to exert anti-inflammatory and organ-protective effects in vivo. We investigated the effects of the volatile anesthetic isoflurane on lung injury during mechanical ventilation. METHODS: C57BL/6N mice were ventilated with a tidal volume of 12 mL/kg body weight for 6 hours in the absence or presence of isoflurane, and, in a second series, with or without the specific phosphoinositide 3-kinase/Akt inhibitor LY294002. Lung injury was determined by comparative histology, and by the isolation of bronchoalveolar lavage for differential cell counting and analysis of cytokine levels using enzyme-linked immunosorbent assays. Lung homogenates were analyzed for protein expression by Western blotting. RESULTS: Mechanical ventilation caused increases in alveolar wall thickening, cellular infiltration, and an elevated ventilator-induced lung injury score. Neutrophil influx and cytokine (i.e., interleukin-1β, and macrophage inflammatory protein-2) release were enhanced in the bronchoalveolar lavage of ventilated mice. The expression levels of the stress proteins hemeoxygenase-1 and heat shock protein-70 were elevated in lung tissue homogenates. Isoflurane ventilation significantly reduced lung damage, inflammation, and stress protein expression. In contrast, phosphorylation of Akt protein was substantially increased during mechanical ventilation with isoflurane. Inhibition of phosphoinositide 3-kinase/Akt signaling before mechanical ventilation completely reversed the lung-protective effects of isoflurane treatment in vivo. CONCLUSIONS: Inhalation of isoflurane during mechanical ventilation protects against lung injury by preventing proinflammatory responses. This protection is mediated via phosphoinositide 3-kinase/Akt signaling....
- Open Access
- 1 January 2012
- Published by Springer Nature in Medical Gas Research
- Vol. 2 (1) , 26
Inhaled hydrogen sulfide protects against lipopolysaccharide-induced acute lung injury in mice
Local pulmonary and systemic infections can lead to acute lung injury (ALI). The resulting lung damage can evoke lung failure and multiple organ dysfunction associated with increased mortality. Hydrogen sulfide (H2S) appears to represent a new therapeutic approach to ALI. The gas has been shown to mediate potent anti-inflammatory and organ protective effects in vivo. This study was designed to define its potentially protective role in sepsis-induced lung injury.
- 1 January 2012
- Published by Springer Nature in Medical Gas Research
- Vol. 2 (1) , 26
Open AccessInhaled hydrogen sulfide protects against lipopolysaccharide-induced acute lung injury in mice
Local pulmonary and systemic infections can lead to acute lung injury (ALI). The resulting lung damage can evoke lung failure and multiple organ dysfunction associated with increased mortality. Hydrogen sulfide (H2S) appears to represent a new therapeutic approach to ALI. The gas has been shown to mediate potent anti-inflammatory and organ protective effects in vivo. This study was designed to define its potentially protective role in sepsis-induced lung injury.
- 1 December 2010
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 11 (12) , 1495-1503
Regulatory role of anesthetics on heme oxygenase-1.
Abstract: As an enzyme, heme oxygenase (HO) can provide substantial cellular protection. By eliminating free heme and generating iron, biliverdin, as well as carbon monoxide, HO exerts anti-inflammatory, anti-proliferative, antioxidative, and vasodilatory effects. The inducible form of HO, heme oxygenase-1 (HO-1) can be upregulated by harmful stimuli in most human cell types. In such a way, cells utilize HO-1 as a mechanism of self-protection. Many studies have shown that upregulation of HO-1 prior to injurious stimuli conferred protection to cells and organs against subsequent injury. Therefore, manipulation of HO-1 gene expression might represent a valuable strategy for the prevention of organ dysfunction. In recent studies, intravenous and inhaled anesthetics (e.g., ketamine, propofol, opioids, isoflurane, sevoflurane, desflurane, etc.) not only upregulate HO-1 to varying extents, but account for organ protection via the HO pathway. The major advantage of anesthetics over other HO-inducing agents is related to their clinically proven safety. Another important issue is that patients receiving anesthetics in anesthesia or intensive care medicine are often suffering from pathological conditions involving pro-oxidative or pro-inflammatory states. Therefore, it would be interesting to know whether the impact of anesthetics on HO-1 regulation might influence outcome of these patients. This overview summarizes the effects of different anesthetics on HO-1 regulation and function in disease models.
- 1 December 2010
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 11 (12) , 1495-1503
Regulatory role of anesthetics on heme oxygenase-1.
Abstract: As an enzyme, heme oxygenase (HO) can provide substantial cellular protection. By eliminating free heme and generating iron, biliverdin, as well as carbon monoxide, HO exerts anti-inflammatory, anti-proliferative, antioxidative, and vasodilatory effects. The inducible form of HO, heme oxygenase-1 (HO-1) can be upregulated by harmful stimuli in most human cell types. In such a way, cells utilize HO-1 as a mechanism of self-protection. Many studies have shown that upregulation of HO-1 prior to injurious stimuli conferred protection to cells and organs against subsequent injury. Therefore, manipulation of HO-1 gene expression might represent a valuable strategy for the prevention of organ dysfunction. In recent studies, intravenous and inhaled anesthetics (e.g., ketamine, propofol, opioids, isoflurane, sevoflurane, desflurane, etc.) not only upregulate HO-1 to varying extents, but account for organ protection via the HO pathway. The major advantage of anesthetics over other HO-inducing agents is related to their clinically proven safety. Another important issue is that patients receiving anesthetics in anesthesia or intensive care medicine are often suffering from pathological conditions involving pro-oxidative or pro-inflammatory states. Therefore, it would be interesting to know whether the impact of anesthetics on HO-1 regulation might influence outcome of these patients. This overview summarizes the effects of different anesthetics on HO-1 regulation and function in disease models.
- 1 July 2010
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 113 (1) , 104-115
Inhaled Hydrogen Sulfide Protects against Ventilator-induced Lung Injury
Background: Mechanical ventilation still causes an unacceptably high rate of morbidity and mortality because of ventilator-induced lung injury (VILI). Therefore, new therapeutic strategies are needed to treat VILI. Hydrogen sulfide can induce hypothermia and suspended animation-like states in mice. Hydrogen sulfide can also confer antiinflammatory and antiapoptotic effects. This study investigates the organ-protective effects of inhaled hydrogen sulfide during mechanical ventilation. Methods: Mice were ventilated with a tidal volume of 12 ml/kg body weight for 6 h with synthetic air in the absence or presence of hydrogen sulfide (80 parts per million) and, in a second series, at either mild hypothermia or normothermia. Staining of lung sections determined the degree of lung damage by VILI score and apoptotic cells. Bronchoalveolar lavage fluid was analyzed for the cytokines interleukin-1beta and macrophage inflammatory protein-1beta and for neutrophil accumulation. Heme oxygenase-1 and heat shock protein 70 expression were assessed in the lung tissue by Western immunoblot analysis. Results: Mechanical ventilation at both hypothermia and normothermia led to a profound development of VILI, characterized by pulmonary edema, increased apoptosis, cytokine release, neutrophil recruitment, and up-regulation of the stress proteins such as heme oxygenase-1 and heat shock protein 70. In contrast, the application of hydrogen sulfide during ventilation at either mild hypothermia or normothermia prevented edema formation, apoptosis, proinflammatory cytokine production, neutrophil accumulation, and inhibited heme oxygenase-1 expression. Conclusions: Inhalation of hydrogen sulfide during mechanical ventilation protects against VILI by the inhibition of inflammatory and apoptotic responses. Hydrogen sulfide confers lung protection independently of its ability to induce mild hypothermia during ventilation.
- 1 July 2010
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 113 (1) , 104-115
Inhaled Hydrogen Sulfide Protects against Ventilator-induced Lung Injury
Background: Mechanical ventilation still causes an unacceptably high rate of morbidity and mortality because of ventilator-induced lung injury (VILI). Therefore, new therapeutic strategies are needed to treat VILI. Hydrogen sulfide can induce hypothermia and suspended animation-like states in mice. Hydrogen sulfide can also confer antiinflammatory and antiapoptotic effects. This study investigates the organ-protective effects of inhaled hydrogen sulfide during mechanical ventilation. Methods: Mice were ventilated with a tidal volume of 12 ml/kg body weight for 6 h with synthetic air in the absence or presence of hydrogen sulfide (80 parts per million) and, in a second series, at either mild hypothermia or normothermia. Staining of lung sections determined the degree of lung damage by VILI score and apoptotic cells. Bronchoalveolar lavage fluid was analyzed for the cytokines interleukin-1beta and macrophage inflammatory protein-1beta and for neutrophil accumulation. Heme oxygenase-1 and heat shock protein 70 expression were assessed in the lung tissue by Western immunoblot analysis. Results: Mechanical ventilation at both hypothermia and normothermia led to a profound development of VILI, characterized by pulmonary edema, increased apoptosis, cytokine release, neutrophil recruitment, and up-regulation of the stress proteins such as heme oxygenase-1 and heat shock protein 70. In contrast, the application of hydrogen sulfide during ventilation at either mild hypothermia or normothermia prevented edema formation, apoptosis, proinflammatory cytokine production, neutrophil accumulation, and inhibited heme oxygenase-1 expression. Conclusions: Inhalation of hydrogen sulfide during mechanical ventilation protects against VILI by the inhibition of inflammatory and apoptotic responses. Hydrogen sulfide confers lung protection independently of its ability to induce mild hypothermia during ventilation.
- 29 February 2008
- Published by Elsevier in Nitric Oxide
- Vol. 18 (1) , 61-69
Nitric oxide-deficiency regulates hepatic heme oxygenase-1
- 29 February 2008
- Published by Elsevier in Nitric Oxide
- Vol. 18 (1) , 61-69
Nitric oxide-deficiency regulates hepatic heme oxygenase-1
- 1 October 2006
- Published by Springer Nature in Der Anaesthesist
- Vol. 55 (10) , 1068-1079
Kohlenmonoxid – Gift oder potenzielles Therapeutikum?
Kohlenmonoxid (CO) ist weit mehr als nur ein toxisches Gas. Es wird endogen durch das Enzym Hämoxygenase synthetisiert und erfüllt essenzielle Funktionen unter physiologischen und pathophysiologischen Bedingungen. Untersuchungen der letzten Jahre attestieren CO antioxidative, antiinflammatorische, antiproliferative, antiapoptotische und vasodilatative Eigenschaften. Insbesondere bei anästhesiologisch und intensivmedizinisch relevanten Krankheitsbildern, wie dem „adult respiratory distress syndrome“ (ARDS), der Sepsis oder bei Organtransplantationen konnten in experimentellen Modellen zytoprotektive Wirkungen durch niedrig dosierte CO-Applikation nachgewiesen werden. Im Hinblick auf eine potenzielle therapeutische Anwendung beim Menschen werden in dieser Übersichtsarbeit funktionelle, protektive und toxische Wirkungen im Kontext des aktuellen Wissensstands kritisch diskutiert. Carbon monoxide (CO) is much more than just a toxic gas. Carbon monoxide is produced endogenously by the enzyme heme oxygenase and has important functions under physiological and pathophysiological conditions. Recent studies suggested antioxidative, anti-inflammatory, antiproliferative, anti-apoptotic, and vasodilating characteristics. Regarding clinically-relevant diseases in anesthesiology and critical care medicine, such as adult respiratory distress syndrome (ARDS), sepsis, or during organ transplantation, cytoprotective properties have been demonstrated by low-dose CO in experimental models. In view of a potential CO application in future human studies, this review discusses what is known to date about CO as it relates to functional, protective and toxic aspects.
- 1 October 2006
- Published by Springer Nature in Der Anaesthesist
- Vol. 55 (10) , 1068-1079
Kohlenmonoxid – Gift oder potenzielles Therapeutikum?
Kohlenmonoxid (CO) ist weit mehr als nur ein toxisches Gas. Es wird endogen durch das Enzym Hämoxygenase synthetisiert und erfüllt essenzielle Funktionen unter physiologischen und pathophysiologischen Bedingungen. Untersuchungen der letzten Jahre attestieren CO antioxidative, antiinflammatorische, antiproliferative, antiapoptotische und vasodilatative Eigenschaften. Insbesondere bei anästhesiologisch und intensivmedizinisch relevanten Krankheitsbildern, wie dem „adult respiratory distress syndrome“ (ARDS), der Sepsis oder bei Organtransplantationen konnten in experimentellen Modellen zytoprotektive Wirkungen durch niedrig dosierte CO-Applikation nachgewiesen werden. Im Hinblick auf eine potenzielle therapeutische Anwendung beim Menschen werden in dieser Übersichtsarbeit funktionelle, protektive und toxische Wirkungen im Kontext des aktuellen Wissensstands kritisch diskutiert. Carbon monoxide (CO) is much more than just a toxic gas. Carbon monoxide is produced endogenously by the enzyme heme oxygenase and has important functions under physiological and pathophysiological conditions. Recent studies suggested antioxidative, anti-inflammatory, antiproliferative, anti-apoptotic, and vasodilating characteristics. Regarding clinically-relevant diseases in anesthesiology and critical care medicine, such as adult respiratory distress syndrome (ARDS), sepsis, or during organ transplantation, cytoprotective properties have been demonstrated by low-dose CO in experimental models. In view of a potential CO application in future human studies, this review discusses what is known to date about CO as it relates to functional, protective and toxic aspects.